On September 9, Shanghai Ruiang Gene Technology Co., Ltd. (hereinafter referred to as Ruiang Gene) issued an announcement stating that Xiong Hui, the company's chairman, applied to resign from the position of chairman, director, general manager and core technical personnel of the company due to personal reasons. After resigning, she will hold other positions in the company.
Riang Gene said that after Xiong Hui resigned, she was still the actual controller of the company, and the company's daily operations and technical research and development were normal. The position of chairman of the company will be taken over by Xiong Hui's husband Gao Shang.
Xiong Hui was born in 1972 and is 53 years old this year. According to Rui'ang Gene's 2025 semi-annual report, Xiong Hui graduated from Fudan University's microbiology major and successfully developed the first HBV drug-resistant mutation detection kit based on a first-generation sequencing platform in China for clinical use.
In July 2024, the company received a notice from Xiong Hui's family, the actual controller, the then director and then deputy general manager Xiong Jun's family, the then deputy general manager He Junyan's family, and the then deputy general manager Xue Yuwei's family,Xiong Hui, Xiong Jun and Xue Yuwei were taken to residential surveillance by the public security organs for suspected illegal operation, while He Junyan was taken to criminal detention by the public security organs for suspected illegal operation.
In October 2024, the company received a notice from the family members of the above-mentioned personnel, and the compulsory measures of Xiong Hui, Xiong Jun, Xue Yuwei and He Junyan were changed to criminal detention, and suspected of being changed to fraud.
In December 2024, Xiong Hui and Xiong Jun have been arrested on suspicion of fraud. The case has entered the stage of review and prosecution by the procuratorate. The relevant facts and nature are still to be further confirmed.
The company's official website shows that Ruiang Gene was established in 2012. The company's main business is the research and development, production, sales, scientific research and testing services of in vitro diagnostic products (including detection instruments and detection reagents). It mainly provides accurate detection of genes and antigens for patients with hematopathy (leukemia, lymphoma), solid tumors (lung cancer, colorectal cancer, melanoma, etc.) and infectious diseases (hepatitis B, rubella, herpes simplex, etc.).
Source | Qingdao Daily comprehensive Shanghai Stock Exchange website, China Business News, etc.
